Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.50 |
| ▸ | MPL | P40238 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 7/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886802 | 0.79 | MPL (0.46) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL1886904 | 0.78 | FEN1 (0.50) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL1658180 | 0.75 | FEN1 (0.47) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL23255324 | 0.73 | CYP11B2 (0.50) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL17255938 | 0.73 | GAA (0.33) | — | |
| SCHEMBL31058977 | 0.72 | CYP11B1 (0.34) | CYP11B2CYP11B1 | |
| SCHEMBL26152275 | 0.72 | CYP11B1 (0.34) | CYP11B2CYP11B1 | |
| SCHEMBL1890443 | 0.72 | FEN1 (0.44) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL23255418 | 0.71 | CYP1A2 (0.55) | CYP11B2CYP11B1MPLFEN1ALOX5AP | |
| SCHEMBL16654277 | 0.69 | CYP11B2 (0.64) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| CN-101970406-A | Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors | NEUROSEARCH AS | 2011-02-09 | — | — | CN | disclosed |
| EP-2262767-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009112461-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | CYP11B2 1545/4885CYP11B1 1354/4885MPL 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.